➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Moodys
McKesson
Medtronic
Harvard Business School

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VIBEGRON

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Vibegron

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01314872 A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) Completed Merck Sharp & Dohme Corp. Phase 2 2011-03-01 This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB). The primary hypothesis of the base study is that administration of vibegron demonstrates a dose-related reduction, compared with placebo, in average number of daily micturitions in participants with OAB after 8 weeks of treatment.
NCT01500382 A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) Terminated Merck Sharp & Dohme Corp. Phase 1 2012-02-01 The study is designed to investigate the effects of the investigational drug vibegron (MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive bladder. The study will also evaluate the safety and tolerability of multiple oral doses of vibegron in women with overactive bladder. Overactive bladder is best described as urgency and frequency of urination, with or without involuntary urination and/or the need to awaken during the night to urinate. The primary efficacy hypothesis is that vibegron is superior to placebo with respect to change from baseline in maximum cystometric capacity at 2 hours postdose on Day 7 (i.e., steady state) in participants with overactive bladder. A true mean increase (vibegron/placebo) of 25% in bladder volume is expected. The primary safety hypothesis is that administration of multiple oral doses of vibegron is sufficiently well-tolerated in participants with overactive bladder, based on assessment of clinical and laboratory adverse experiences, to permit continued clinical investigation.
NCT01628042 A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) Completed Merck Sharp & Dohme Corp. Phase 1 2012-07-01 This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of vibegron (MK-4618) to guide use of vibegron in clinical trials in participants with overactive bladder and to guide recommendations on potential dosing adjustments for individuals with varying degrees of renal impairment.
NCT01737684 A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) Completed Merck Sharp & Dohme Corp. Phase 1 2013-01-01 This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index (BMI). Participants may be enrolled with mild hepatic insufficiency.
NCT03492281 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) Recruiting Urovant Sciences GmbH Phase 3 2018-03-26 This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
NCT03583372 An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Active, not recruiting Urovant Sciences GmbH Phase 3 2018-06-14 This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB for up to 52 weeks.
NCT03806127 Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome Recruiting Urovant Sciences GmbH Phase 2 2018-12-31 This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vibegron

Condition Name

Condition Name for Vibegron
Intervention Trials
Overactive Bladder 7
Urinary Bladder, Overactive 1
Overactive Urinary Bladder 1
Irritable Bowel Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vibegron
Intervention Trials
Urinary Bladder, Overactive 8
Prostatic Hyperplasia 2
Hyperplasia 2
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vibegron

Trials by Country

Trials by Country for Vibegron
Location Trials
United States 114
Poland 7
Canada 4
Hungary 1
Lithuania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vibegron
Location Trials
Indiana 5
California 5
Alabama 5
Texas 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vibegron

Clinical Trial Phase

Clinical Trial Phase for Vibegron
Clinical Trial Phase Trials
Phase 3 4
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vibegron
Clinical Trial Phase Trials
Completed 3
Recruiting 3
Enrolling by invitation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vibegron

Sponsor Name

Sponsor Name for Vibegron
Sponsor Trials
Urovant Sciences GmbH 5
Merck Sharp & Dohme Corp. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vibegron
Sponsor Trials
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Moodys
Boehringer Ingelheim
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.